Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 2:2019:3945672.
doi: 10.1155/2019/3945672. eCollection 2019.

Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials

Affiliations
Review

Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials

Maria P de Miguel et al. Stem Cells Int. .

Abstract

The liver centralizes the systemic metabolism and thus controls and modulates the functions of the central and peripheral nervous systems, the immune system, and the endocrine system. In addition, the liver intervenes between the splanchnic and systemic venous circulation, determining an abdominal portal circulatory system. The liver displays a powerful regenerative potential that rebuilds the parenchyma after an injury. This regenerative mission is mainly carried out by resident liver cells. However, in many cases this regenerative capacity is insufficient and organ failure occurs. In normal livers, if the size of the liver is at least 30% of the original volume, hepatectomy can be performed safely. In cirrhotic livers, the threshold is 50% based on current practice and available data. Typically, portal vein embolization of the part of the liver that is going to be resected is employed to allow liver regeneration in two-stage liver resection after portal vein occlusion (PVO). However, hepatic resection often cannot be performed due to advanced disease progression or because it is not indicated in patients with cirrhosis. In such cases, liver transplantation is the only treatment possibility, and the need for transplantation is the common outcome of progressive liver disease. It is the only effective treatment and has high survival rates of 83% after the first year. However, donated organs are becoming less available, and mortality and the waiting lists have increased, leading to the initiation of living donor liver transplantations. This type of transplant has overall complications of 38%. In order to improve the treatment of hepatic injury, much research has been devoted to stem cells, in particular mesenchymal stem cells (MSCs), to promote liver regeneration. In this review, we will focus on the advances made using MSCs in animal models, human patients, ongoing clinical trials, and new strategies using 3D organoids.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histological images of a normal rat (a) and long-term cholestatic (b) liver parenchyma. Note the severe epithelial bile cell proliferation associated with fibrosis and hepatocyte death by necrosis and apoptosis in (b). V: portal vein, A: hepatic artery, B: biliary duct, and H: hepatocytes.
Figure 2
Figure 2
In the liver, the ductular reactions (bottom) could adopt ductal plate configurations (superior). In addition, the normal hepatic structure, represented by a functional hepatic unit (middle), is also based on the ductal plate configuration.
Figure 3
Figure 3
Mesenchymal stem cells in culture under phase-contrast microcopy. (a) Bone marrow-derived MSC. (b) Adipose tissue-derived MSC. Original magnification 200x.

Similar articles

Cited by

References

    1. Sherlock S. Diseases of the Liver and Biliary System. Wiley; 2007. The portal venous system and portal hypertension; pp. 147–186. - DOI
    1. Preziosi M. E., Monga S. P. Update on the mechanisms of liver regeneration. Seminars in Liver Disease. 2017;37(02):141–151. doi: 10.1055/s-0037-1601351. - DOI - PMC - PubMed
    1. Rockey D. C. Hepatic fibrosis, stellate cells, and portal hypertension. Clinics in Liver Disease. 2006;10(3):459–479. doi: 10.1016/j.cld.2006.08.017. - DOI - PubMed
    1. Tsochatzis E. A., Bosch J., Burroughs A. K. Liver cirrhosis. The Lancet. 2014;383(9930):1749–1761. doi: 10.1016/S0140-6736(14)60121-5. - DOI - PubMed
    1. Reddy S. S., Civan J. M. From Child-Pugh to model for end-stage liver disease: deciding who needs a liver transplant. Medical Clinics of North America. 2016;100(3):449–464. doi: 10.1016/j.mcna.2015.12.002. - DOI - PubMed

LinkOut - more resources